Dr Adam Brown Hess, PHD in Alexandria, LA - Medicare Clinical Psychologist Provider

Dr Adam Brown Hess, PHD is a medicare enrolled "Psychologist" provider in Alexandria, Louisiana. He graduated from medical school in 2008 and has 16 years of diverse experience with area of expertise as Clinical Psychologist. He is a member of the group practice Red River Behavioral Health, Llc and his current practice location is 3033 Jackson St, Alexandria, Louisiana. You can reach out to his office (for appointments etc.) via phone at (318) 794-3801.

Dr Adam Brown Hess is licensed to practice in Louisiana (license number 1174) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1609153303.

Contact Information

	Dr Adam Brown Hess, PHD
	3033 Jackson St, Alexandria, LA 71301-4744
	(318) 794-3801
	Not Available

Healthcare Provider's Profile

Full Name	Dr Adam Brown Hess
Gender	Male
Speciality	Clinical Psychologist
Experience	16 Years
Location	3033 Jackson St, Alexandria, Louisiana
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Adam Brown Hess graduated from medical school in 2008

NPI Data:

NPI Number: 1609153303
Provider Enumeration Date: 11/08/2011
Last Update Date: 11/08/2011

Medicare PECOS Information:

PECOS PAC ID: 3577726736
Enrollment ID: I20210916001544

Medical Identifiers

Medical identifiers for Dr Adam Brown Hess such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1609153303	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103T00000X	Psychologist	1174 (Louisiana)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Red River Behavioral Health, Llc	2668635822	2

News Archive

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

Native Hawaiians have highest risk for pancreatic cancer, study shows

Native Hawaiians are at highest risk for pancreatic cancer, according to a USC study that provides a surprising look at disparities surrounding the deadly disease.

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

The rate of Kawasaki disease in South Korea has substantially decreased during the COVID-19 pandemic, possibly due to pandemic prevention efforts, such as mask-wearing, hand-washing and physical distancing, according to new research published today in the American Heart Association's flagship journal Circulation.

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Adam Brown Hess allows following entities to bill medicare on his behalf.

Entity Name	Red River Behavioral Health, Llc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1134491855 PECOS PAC ID: 2668635822 Enrollment ID: O20120525000270

News Archive

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Native Hawaiians have highest risk for pancreatic cancer, study shows

Native Hawaiians are at highest risk for pancreatic cancer, according to a USC study that provides a surprising look at disparities surrounding the deadly disease.

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

VIVUS seeks marketing approval of QNEXA in the EU

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Adam Brown Hess is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Adam Brown Hess, PHD Po Box 12368, Alexandria, LA 71315-2368 Ph: (318) 794-3801	Dr Adam Brown Hess, PHD 3033 Jackson St, Alexandria, LA 71301-4744 Ph: (318) 794-3801

News Archive

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Native Hawaiians have highest risk for pancreatic cancer, study shows

Native Hawaiians are at highest risk for pancreatic cancer, according to a USC study that provides a surprising look at disparities surrounding the deadly disease.

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

VIVUS seeks marketing approval of QNEXA in the EU

Psychologist in Alexandria, LA

Dr. Darrel Bonelle Turner, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 620 Hummingbird Ln, Alexandria, LA 71303 Phone: 936-355-1618
Dr. Samantha Jean Tippy, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 4814 Westgarden Blvd, Alexandria, LA 71303 Phone: 815-210-5045
Lauren Drerup Stokes, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1016 Calais Cir, Alexandria, LA 71303 Phone: 318-442-7355 Fax: 318-442-4407
Tonya Sue Jackson, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 5411 Coliseum Blvd, Alexandria, LA 71303 Phone: 318-484-2347
Dr. David Clifford Daniel Jr., PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2495 Shreveport Hwy 71n, 116b Psychology Clinic, Alexandria, LA 71306 Phone: 318-473-0010 Fax: 318-483-5096
Dr. Leigh Ann Hess, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 5615 Jackson St Ext Bldg K, Alexandria, LA 71303 Phone: 318-443-7711
Dr. Dana Marie Pollard, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2495 Shreveport Highway, Alexandria, LA 71360 Phone: 318-473-0010

Dr Adam Brown Hess, PHD - Medicare Psychologist in Alexandria, LA

Contact Information

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Native Hawaiians have highest risk for pancreatic cancer, study shows

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

VIVUS seeks marketing approval of QNEXA in the EU

Medicare Reassignments

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Native Hawaiians have highest risk for pancreatic cancer, study shows

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

VIVUS seeks marketing approval of QNEXA in the EU

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Native Hawaiians have highest risk for pancreatic cancer, study shows

Kawasaki disease in children has reduced during COVID-19 due to pandemic prevention efforts

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

VIVUS seeks marketing approval of QNEXA in the EU

Psychologist in Alexandria, LA